Clinical trial · Interventional
Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy
A Prospective Randomized Study Examining the Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-Assisted Laparoscopic Radical Prostatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To date, there is a lack of consensus concerning the optimal timing for removal of the urethral catheter, its related complications, the effectiveness in prophylactic drug use to reduce complication, and the patient reported outcomes (quality of life) after robot-assisted laparoscopic prostatectomy (RALP). The purpose of this study is to determine the impact of tamsulosin on voiding patterns following early urethral catheter removal after RALP for prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms, Prostatectomy | Prostate Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No medication | Other | — | UNRESOLVED |
| tamsulosin 0.4mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Tamsulosin 0.4mg
- description
- Perioperative tamsulosin 0.4mg daily
- interventionNames
- Drug: tamsulosin 0.4mg
- type
- PLACEBO_COMPARATOR
- label
- Control
- description
- No medication
- interventionNames
- Other: No medication
Primary outcomes (1)
- measure
- The incidence of acute urinary retention
- timeFrame
- within the 30 days after surgery
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients must have localized or locally advanced prostate cancer * Patients must receive robot assisted laparoscopic radical prostatectomy * Patients must be able to provide written informed consent Exclusion Criteria: * Patients must not have a history of treatment with alpha blockers within 4 weeks * Patients must not have previously undergone transurethral resection, laser therapy, or other surgery of the prostate * Patients must not have previously been diagnosed with neurogenic bladder * Patients must not have hypersensitivity to trial drug or other alpha-blockers * Patients must not have the participation of other clinical trial within the past 3 months
References
Publications (0)
Data not yet available